Loading company…
TRIOAR develops platform technology and drug candidates for cancer and other diseases.
Founded in 2021 and based in Daejeon, South Korea, TRIOAR develops drug platform technology intended to address limitations of antibody therapeutics and antibody-drug conjugates. Its pipeline includes candidates for breast cancer, solid tumors, gastric cancer and other indications. The company raised KRW 12 billion in Series A funding in May 2023 and KRW 22.5 billion in Series B funding in July 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in